CD39/ecto-nucleoside triphosphate diphosphohydrolase-type-1 (ENTPD1) is the dominant vascular ectonucleotidase that catalyzes the phosphohydrolysis of extracellular nucleotides in the blood and extracellular space. This ecto-enzymatic process modulates endothelial cell, leukocyte, and platelet purinergic receptor-mediated responses to extracellular nucleotides in the setting of thrombosis and vascular inflammation. We show here that deletion of Cd39/Entpd1 results in abrogation of angiogenesis, causing decreased growth of implanted tumors and inhibiting development of pulmonary metastases. Qualitative abnormalities of Cd39-null endothelial cell adhesion and integrin dysfunction were demonstrated in vitro. These changes were associated with decreased activation of focal adhesion kinase and extracellular signaling-regulated kinase-1 and -2 in endothelial cells. Our data indicate novel links between CD39/ENTPD1, extracellular nucleotide-mediated signaling, and vascular endothelial cell integrin function that impact on angiogenesis and tumor growth. Copyright © American Society for Investigative Pathology.
CITATION STYLE
Jackson, S. W., Hoshi, T., Wu, Y., Sun, X., Enjyoji, K., Cszimadia, E., … Robson, S. C. (2007). Disordered purinergic signaling inhibits pathological angiogenesis in Cd39/Entpd1-null mice. American Journal of Pathology, 171(4), 1395–1404. https://doi.org/10.2353/ajpath.2007.070190
Mendeley helps you to discover research relevant for your work.